- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Aaron Lyss: Most Practices Are Not Ready to Transition to MACRA
Most practices are not ready to transition to the Medicare Access and CHIP Reauthorization Act (MACRA) payment models, although there is a leading group of practices that are more prepared to make the switch, said Aaron Lyss, director of value-based care for Tennessee Oncology.
Most practices are not ready to transition to the Medicare Access and CHIP Reauthorization Act (MACRA) payment models, although there is a leading group of practices that are more prepared to make the switch, said Aaron Lyss, director of value-based care for Tennessee Oncology.
Transcript (slightly modified)
Are practices ready for the transition to MACRA? Do they understand it, MIPS, APMs, and how the Oncology Care Model fits in?
I’ll give you a short answer—that’s no, I don’t think they are ready. That just speaks to what I see among oncology practices nationwide.
Having said that, there are a leading group of practices on that curve that are much more prepared for what’s happening in this space than others and I think we’re in that cohort of practices that are as ready as any for these types of changes. But, I do think it’s a problem nationwide that a lot of practices just haven’t had the foresight to build the infrastructure and data management capabilities over the past several years. So, they haven’t had the foresight to start several years ago down this road, so they can be in a position to be ready in the near term.
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More
